Enalapril prevents aortic hyperreactivity and remodelling in one-kidney, one-clip hypertensive rats without reducing arterial pressure

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 7, 2000, Pages 474-479

  Cunha, Valdeci ^a,b   Salgado, Helio C ^a   Salgado, Maria Cristina O ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

Author keywords

Angiotensin II; Angiotensin converting enzyme; Enalapril; Endothelium; Nitric oxide; Renal hypertension; Vascular hypertrophy

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTERIAL PRESSURE; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; HEART HYPERTROPHY; HEART OUTPUT; HEMODYNAMICS; HYPERTENSION; MALE; NONHUMAN; RAT; RENOVASCULAR HYPERTENSION; UNINEPHRECTOMY;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BLOOD PRESSURE; ENALAPRIL; HEART; HEMODYNAMIC PROCESSES; HYPERTENSION, RENOVASCULAR; MALE; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, WISTAR;

EID: 0034097946     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03283.x     Document Type: Article

References (37)

1. 1. Weber KT, Anversa FP, Armstrong PW et al. Remodeling and reparation of the cardiovascular system. J. Am. Coll. Cardiol. 1992; 20: 3-16.
2. 2. Philips N, Bashey RI, Jimenez AS. Collagen and fibronectin expression in cardiac fibroblasts from hypertensive rats. Cardiovasc. Res. 1994; 28: 1342-7.
3. 3. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 1987; 9: 178-87.
4. 4. Somlyo AP, Somlyo AV. Vascular smooth muscle. II. Pharmacology of normal and hypertensive vessels. Pharmacol. Rev. 1970; 22: 249-53.
5. 5. Mulvany MJ, Hansen PK, Aalkjaer C. Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cells layers. Circ. Res. 1982; 43: 854-64.
6. 6. Luscher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rats. Hypertension 1986; 8: 344-8.
7. 7. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: From physiology to therapy. J. Mol Cell Cardiol. 1999; 31: 61-74.
8. 8. Dzau VJ, Safur ME. Large conduit arteries in hypertension: Role of the renin-angiotensin system. Circulation 1977; 77: 947-53.
9. 9. Bunkenburg B, Amelsvoort TV, Rogg H, Woord JM. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 1992; 20: 746-54.
10. 10. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res. 1988; 62: 749-56.
11. 11. Brilla CG, Scheer C, Rupp H. Renin-angiotensin system and myocardial collagen matrix: Modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. J. Hypertens. 1997; 15: S13-19.
12. 12. Griffin SA, Brown WCB, MacPherson F et al. Angiotensin II causes vascular hypertrophy in rat by a nonpressor mechanism. Hypertension 1991; 17: 626-35.
13. 13. Rajagopalan S, Kurz S, Munzel T et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 1996; 97: 1916-23.
14. 14. Albaladejo P, Bouaziz H, Duriez M et al. Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats. Hypertension 1994; 23: 74-82.
15. 15. Clozel M, Kuhn H, Baumgartner HR. ACE inhibition and the vascular intima in hypertension. J. Cardiovasc. Pharmacol. 1993; 22 (Suppl.4): S15-18.
16. 16. Rhaleb NE, Yang XP, Scicli AG, Carretero AO. Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension 1994; 23: 865-8.
17. 17. Rizzoni D, Castellano M, Porteri E et al. Effects of low and high doses of fosinopril on the structure and function of resistance arteries. Hypertension 1995; 26: 118-23.
18. 18. Rizzoni D, Castellano M, Porteri E et al. Prolonged effects of short-term fosinopril on blood pressure and vascular morphology and function in rats. Am. J. Hypertens. 1997; 10: 1034-43.
19. 19. Bengis RG, Coleman TG. Antihypertensive effect of prolonged blockade of angiotensin formation in benign and malignant, one-and two-kidney Goldblatt hypertensive rats. Clin. Sci. 1979; 57: 53-62.
20. 20. Leite R, Salgado MCO. Increased vascular formation of angiotensin II in one-kidney, one clip hypertension. Hypertension 1992; 19: 575-81.
21. 21. Yu H, Rakugi H, Higaki J, Morishita R, Mikami H, Ogihara T. The role of activated vascular angiotensin II generation in vascular hypertrophy in one-kidney, one clip hypertensive rats. J. Hypertens. 1993; 11: 1347-55.
22. 22. Wang D-H, Prewitt RL. Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats. Hypertension 1990; 15: 68-77.
23. 23. O'Sullivan JB, Black MJ, Bertran JF, Bobik A. Cardiovascular hypertrophy in one-kidney, one-clip renal hypertensive rats: A role for angiotensin II? J. Hypertens. 1994; 12: 1163-70.
24. 24. Herizi A, Demeilliers B, Jover B, Mimran A. Cardioprotective effect of enalapril in renovascular and angiotensin II hypertension. Clin. Exp. Hypertens. 1997; 19: 953-64.
25. 25. Okamura T, Okunishi H, Ayajiki K, Toda N. Conversion of angiotensin I to angiotensin II in dog isolated renal artery: Role of two different angiotensin II-generating enzymes. J. Cardiovasc. Pharmacol. 1990; 15: 353-9.
26. 26. Hilgers KF, Kuczera M, Wilhelm MJ et al. Angiotensin formation in the isolated rat hindlimb. J. Hypertens. 1989; 7: 789-98.
27. 27. Nishimura H, Buikema H, Baltatu O, Ganten D, Urata H. Functional evidence for alternative ANG II-forming pathways in hamster cardiovascular system. Am. J. Physiol. 1998; 275: H1307-12.
28. 28. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 1990; 265: 22 348-57.
29. 29. Balcells E, Meng QC. Johnson Jr WH, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: Methods and species considerations. Am. J. Physiol. 1997; 273: H1769-74.
30. 30. Neves LA, Almeida AP, Khosla MC, Santos RA. Metabolism of angiotensin I in isolated rat hearts. Effect of angiotensin converting enzyme inhibitors. Biochem. Pharmacol. 1995; 50: 1451-9.
31. 31. Leenen FHH, Myers MG. Pressor mechanisms in renovascular hypertensive rats. In: De Jong W (eds). Handbook of Hypertension, Vol. 4. Experimental and Genetic Models of Hypertension. Elsevier Science, Amsterdam. 1984; 24-53.
32. 32. Leite R, Estevāo R, Resende AC, Salgado MCO. Role of endothelium in angiotensin II formation by the rat aorta and mesenteric arterial bed. Braz. J. Med. Biol. Res. 1997; 30: 649-56.
33. 33. Hoshino J, Sakamaki T, Nakamura T et al. Exaggerated vascular response due to endothelial dysfunction and role of the renin-angiotensin system at early stage of renal hypertension in rats. Circ. Res. 1994; 74: 130-8.
34. 34. Bell DR, Bohr DF. Endothelium in functional aortic changes of coarctation hypertension. Am. J. Physiol. 1991; 260: H1187-93.
35. 35. Wiemer G, Schölkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991; 18: 558-63.
36. 36. Zanzinger J, Zheng X, Bassenge E. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism. Cardiovasc. Res. 1994; 28: 209-14.
37. 37. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997; 29: 274-9.